TNF and anti-neutrophil cytoplasmic antibody-associated vasculitis: The other two cases were associated with RA and ANCA-associated vasculitis, respectively, and were selected by the department of rheumatology to receive molecularly targeted agents other than TNF inhibitors, because of their advanced age and poor general condition.